เดือน: กุมภาพันธ์ 2026

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

- A branding area showcasing Hitachi’s journey from its founding to the vision it aims to achieve through Inspire 2027.(Top left)- A three-sided immersive theater presenting the future of buildings through powerful, engaging visual experiences.(Top right)- The entrance to the exhibition area where visitors can experience Hitachi’s comprehensive capabilities broughttogether under the One Hitachi. (Bottom left)- An interactive corner that visualizes and demonstrates commercial air conditioning control using augmented realitytechnology. (Bottom right)TOKYO, Feb 5, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and Hitachi Building Systems Co., Ltd. (“Hitachi Building Systems”, part of Hitachi’s Connective Industries Sector (“CI Sector”)) will significantly expand the exhibits at “Hitachi Building Solutions Lab”, a customer co-creation research facility. The facility, located in Tokyo, will reopen in its new form on March 2, 2026. The exhibition is being expanded to accelerate digital innovation in the field of buildings, which are bases for people's activities, with a view toward the realization of a harmonized society where the environment, wellbeing and economic growth coexist in harmony as envisioned in the Inspire 2027, Hitachi Group's new management plan. To address social issues, including the decline in the working population and carbon neutrality, the new exhibition will use AI, digital twin, and augmented reality (AR) technologies to propose the latest solutions addressed by One Hitachi, including HMAX for Buildings: BuilMirai, a suite of next-generation solutions that combine domain knowledge and advanced AI.In the future, Hitachi and Hitachi Building Systems will advance collaborative creation with developers, design offices, construction companies, owners of buildings, building management companies and other customers, as well as with partners at the Hitachi Building Solutions Lab.Outline of the new exhibition1. Building management using physical AI realized using digital twin technologiesTo address the labor shortage in building management operations, the new exhibition will propose a future vision for building management in a demonstration that combines AI and digital twin solutions, based on the latest technologies being developed by Hitachi's Research & Development Group. Visitors will be able to experience a digital twin solution for the operation of a guide robot in a physical space after they view optimal solutions proposed by an AI agent based on the results of people flow analyses and provide instructions to the robot in a virtual space.2. Air conditioning and demand control solution to accelerate GX and ZEB*1The exhibition will propose solutions for decarbonizing and reducing energy expenses of buildings with a view toward the achievement of carbon neutrality in 2050. The Hitachi Building Solutions Lab will provide an experience-based exhibition that visualizes the exiida air conditioning IoT solution from Hitachi Global Life Solutions, Inc. (“Hitachi GLS”, part of Hitachi’s CI Sector) and controls an actual business-use air conditioning system using AR technologies.*1 GX: Green Transformation ZEB: Net Zero Energy Building3. Seeking seamless movement within buildings and wellbeingThe exhibition will propose experiences that facilitate seamless movement using integrated elevators and other building equipment with a view toward supporting people's diverse workstyles and increasing the safety and quality of life (QoL) of building users. It will enable visitors to experience the link between the connected features of Hitachi's standard elevator set to be released in April 2026 and mobile robots, connections with the Hybrid-PCS vehicle-to-everything (V2X) system*2 capable of supplying power to elevators and other building equipment by connecting to electric vehicles during a power outage, and the latest security system using an Apple Wallet authentication system*3 .*2 V2X: Vehicle to Everything (Technology enabling electric vehicles, residential houses, buildings and the power grid, etc. to supply power to each other by connecting vehicles to various devices and infrastructure.)*3 Contactless authentication system using smartphones. In this system, users' identification documents and driver's licenses are registered in the Apple Wallet application so that the user's identity and age can be verified in real time using Face ID, Touch ID or NFC.4. Strengthening comprehensive solution capabilities such as One Hitachi To address increasingly diverse and complicated social issues and mission-critical areas, the exhibition will showcase examples of the Hitachi Group's solutions in its broad range of business sectors centered on HMAX for Buildings and products in the CI Sector. They will include AI safety solutions*4 to facilitate increased work efficiency and improved safety for frontline engineers, Hitachi Industrial Equipment Systems Co., Ltd.'s generative AI agent for the provision of dialogue-based information on the operation and maintenance of industrial equipment, and Hitachi GLS' connected home appliances. This will strengthen Hitachi's comprehensive ability to propose solutions as One Hitachi.*4 News released on November 14, 2025: Hitachi Commences the On-Site Application of an AI-Based Safety Solution for Engineers in the Field — Dangerous Location Notification https://www.hitachi.com/New/cnews/month/2025/11/251114a.htmlOutline of the Hitachi Building Solutions Lab Address : 4-16-29 Nakagawa, Adachi-ku, TokyoDate of opening : April 2, 2023Closed on : Saturdays, Sundays, national holidays and Hitachi's non-business daysOperating hours : 10:00 a.m. to 5:00 p.m.Tour style : Fully attended tours by reservation only (In principle, tours are open only to developers, design offices, constructors, owners of buildings, management associations and other customers and partners.)Hitachi’s CI Sector focuses on “Integrated Industry Automation,” which aims to expand “HMAX Industry” into growth industries horizontally. HMAX Industry provides next-generation solutions for industry field that combine data from an abundant installed base of products (digitalized assets), domain knowledge, and advanced AI. As part of the CI Sector, Hitachi Building Systems aims to drive innovation for frontline engineers and contribute to improving people's wellbeing through the delivery of HMAX for Buildings: BuilMirai that embodies Lumada 3.0.An exhibit introducing AI safety solution for frontline engineers and Hitachi’s smart building services through digitalsignage, highlighting on-site transformation powered by AI.Trademark Notice: All trademarks and product names are the property of their respective owners.Hitachi Building Systems Websitehttps://www.hbs.co.jp/Hitachi Global Websitehttps://www.hitachi.com/businesses/elevator/About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, February 3,2026 - (JCN Newswire via SeaPRwire.com) - Japantastics, Inc, a Tokyo-based company dedicated to promoting and distributing authentic Japan-made products to a global audience, has announced the official launch of Japantastics.jp, an online commerce platform that discovers and promotes unique, high-quality Japan-made products - focusing on craftsmanship, engineering, and stories that have long remained hidden beyond Japan's borders.Japan is home to a remarkable depth of artisanal skill and manufacturing excellence. Yet while global interest in Japan continues to rise — reflected in 40+ million visitors in 2025 — many highly skilled artisans and small manufacturers remain oriented entirely toward the domestic market. As a result, much of Japan’s finest craftsmanship remains difficult to encounter outside the country.Japantastics was founded to fill this divide, and curate products based on craft integrity, technical excellence, and cultural context, introducing makers whose work reflects years—often decades—of dedication and refinement. Rather than functioning as a conventional e-commerce marketplace, the Japantastics platform serves to discover and illuminate unique Japan-made crafts and products and will continue to broaden its lineup by discovering and introducing exceptional, lesser-known items from across the country.“Interest in premium Japanese products abroad continues to expand,” said Aki Tsukioka, Co-founder of Japantastics, Inc. "However, many artisans lack the resources, language support, and international channels needed to reach customers overseas. Japantastics exists to bridge that gap—not by simply selling products, but by communicating the value systems, techniques, and stories behind them."At the core of Japantastics is a belief that truly meaningful products are not disposable commodities, but lifelong tools shaped by human intention. By working closely with artisans and manufacturers, the company aims to present Japan-made goods not as trends, but as enduring objects that reward long-term use and appreciation. Each product is introduced with its background, production philosophy, and practical relevance for modern life.The Japantastics platform will continue to expand its lineup by discovering lesser-known makers across Japan - ranging from traditional crafts to contemporary manufacturing - while maintaining a highly selective, story-driven approach to curation. With this model, Japantastics positions itself as a cultural bridge: connecting Japanese creators with global audiences who value authenticity, quality, and depth over mass production.About JapantasticsJapantastics, Inc. is a Tokyo-based company dedicated to introducing authentic Japan-made products to global audiences. Through careful curation and storytelling, the company connects Japanese artisans and small manufacturers with customers worldwide who seek products defined by craftsmanship, longevity, and cultural meaning. Visit Japantastics.jp.Media Contact: Japantastics, Inc. Email: japantastics@gmail.com Website: https://japantastics.jp  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

KYOTO, Japan, Feb. 4, 2026 - (JCN Newswire via SeaPRwire.com) - Valuufy, a Kyoto-based stakeholder impact intelligence company, today released a whitepaper analyzing the nine Nikkei 225 automakers,* and six international benchmarks,** across 168 validated performance metrics, with comparative benchmarking. The findings reveal a 55-point gap between policy commitment and verification performance, reflecting the industry-wide challenge of building measurement infrastructure to match ambitious commitments.Japanese automakers are major competitors in global markets and represent significant holdings in international portfolios. For investors evaluating automotive holdings, this gap creates material uncertainty, but also an opportunity for those who can identify which companies back their commitments with measurable outcomes.[Fig.1: Impact Research Paper - Executive Summary Page].Despite policy commitments averaging 77% across all ValuuCompass impact topics, only 22% translate to quantified outcomes, and just 10% receive third-party verification. This creates potential risk for investors relying on unverified disclosure data, and reflects the industry-wide challenge of building measurement infrastructure to match ambitious commitments.The Measurement Gap"The 55-point policy-performance gap represents fundamental infrastructure deficiencies in translating policy into measurable action," said Kyle Barnes, CEO of Valuufy. "Companies with unsubstantiated claims face potential regulatory scrutiny and reputational damage as verification standards tighten under emerging regulations, including the EU's CSRD and Japan's SSBJ."Value Washing: Beyond Greenwashing"Value washing occurs when companies make stakeholder commitments exceeding actual delivery," said Dr Philip Sugai, Director of Research at Valuufy. "Unlike greenwashing, which focuses on environmental claims, value washing extends across all seven stakeholder groups, including the company, its employees, customers, partners, society, nature and shareholders. The opposite is Value Hushing: when companies achieve strong results but fail to disclose them due to measurement infrastructure gaps."The assessment identified critical measurement blind spots in channel partners, where most environmental and human rights impacts concentrate, and society, including community relationships essential for operational continuity. Only 34% of channel partner metrics have calculation-ready disclosures, while 12% of industry disclosures are claims without quantitative support.Verification Patterns: Japan and International ComparisonJapanese automakers demonstrate comprehensive policy commitments but lower third-party verification rates, averaging 5% compared to 18% for the international peers assessed. This pattern may reflect corporate governance approaches that emphasize internal control over external validation.Among international manufacturers included in the benchmarking, Volkswagen leads with a verification rate of 34%, followed by Hyundai at 26% and BYD at 23%.[Fig.2: Impact Report - Auto Sector Rankings Page]."Building proper measurement infrastructure takes 3-5 years," Barnes added. "Companies starting now can achieve operational maturity by 2028-2029, positioning themselves to meet emerging regulatory requirements across jurisdictions."This Japan automotive analysis is the first in a series of industry reports using ValuuCompass methodology. Valuufy will publish sector-specific assessments throughout 2026. Expanded coverage of international automotive markets is available on demand for investors and companies seeking broader benchmarking.*Nikkei 225 Automakers: Toyota, Honda, Nissan, Suzuki, Mazda, Subaru, Mitsubishi Motors, Isuzu, Hino Motors.**International Automakers: Volkswagen, Hyundai, BYD, Ford, Tesla, General Motors.Download the whitepaper:  www.valuufy.com/automotive-analysis Media Contact: Marco Koeder, Chief Operating Officer, Valuufy. E: marco@valuufy.comRequest a briefing or pilot assessment: learnmore@valuufy.comAbout ValuuCompassValuuCompass(TM) is the stakeholder intelligence platform used in this analysis. Built on over a decade of academic research at Doshisha University's Value Research Center, it measures performance across seven stakeholder dimensions using 168 validated metrics. Unlike traditional black-box ESG ratings, ValuuCompass delivers transparent, glass-box measurement where methodology is fully visible. Companies use it to identify measurement gaps and strengthen disclosure infrastructure. Investors use it to benchmark holdings and assess verification maturity. The platform has been validated through Fortune 500 pilot programs and has been featured at the UN Science Summit for the last four years.About ValuufyValuufy is a Kyoto-based stakeholder impact intelligence company founded in 2024, emerging from over a decade of academic research at Doshisha University's Value Research Center. The company delivers impact measurement, competitive benchmarking, and analysis for investors and organizations. Featured for four consecutive years at the UN Science Summit and recognized as a TiE50 Top 50 Global Startup 2025 and Rising Star at Global Startup Expo 2025, Valuufy is guided by an Advisory Council including former leaders from Apple, Cisco Systems, Sustainalytics and S&P Global. https://valuufy.com.[Fig.3: Japan Automobile Manufacturers' Impact Measurement Challenge]DisclaimerThis analysis is based on publicly available information only and does not constitute investment advice, financial guidance, or any form of professional recommendation. Performance metrics reflect the percentage of quantified outcomes reported across 168 indicators (maximum 100%). Data was collected and analyzed between October 2025 and January 2026. Companies may have updated their disclosures after this period. The findings reflect Valuufy's independent assessment methodology and may differ from other analytical frameworks. Mention of specific companies does not constitute endorsement or criticism beyond the factual observations presented. Full disclaimer: www.valuufy.com/disclaimer Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 4, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI, TSE Code: 7011) announced that order intake increased 12.6% year-on-year to ¥5,029.1 billion in the three quarters ended December 31, 2025. Revenue rose 9.2% year-on-year to ¥3,326.9 billion, resulting in profit from business activities (business profit) of ¥301.2 billion, a 25.5% increase over the previous fiscal year, which represented a business profit margin of 9.1%. Profit attributable to owners of parent (net income) was ¥210.9 billion, an increase of 22.6% year-on-year, with a net income margin of 6.3%. EBITDA was ¥393.1 billion, a 21.0% increase over Q1-3 FY2024, with an EBITDA margin of 11.8%.(billion yen, except where otherwise stated)Q1-3 FY2025 Financial ResultsQ1-3 FY2024 (Note)Q1-3 FY2025YoYYoY%Order Intake4,468.15,029.1+561.0+12.6%Revenue3,047.03,326.9+279.9+9.2%Profit from Business ActivitiesProfit Margin240.17.9%301.29.1%+61.1+1.2 pts+25.5%-Profit Attributable to Owners of ParentProfit Margin172.15.6%210.96.3%+38.8+0.7 pts+22.6%-EBITDAEBITDA Margin324.910.7%393.111.8%+68.1+1.1 pts+21.0%-FCF-143.7167.6+311.4-(Note) Q1-3 FY2024 results have been retroactively adjusted to reflect the planned sale of Mitsubishi Logisnext (ML) shares. For more information on the ML sale, please refer to the following press release published on September 30, 2025: ML Sale Announcement(billion yen, except where otherwise stated)Q1-3 FY2025 Financial Results by SegmentOrder IntakeRevenueBusiness ProfitQ1-3FY2025YoY (Note)Q1-3FY2025YoY (Note)Q1-3FY2025YoY (Note)Energy Systems (Energy)2,857.0+889.91,354.7+75.9146.7-7.7Plants & Infrastructure Systems (P&I)891.3+77.7633.9+47.464.9+25.2Logistics, Thermal & Drive Systems (LT&D)444.3-46.6437.0-27.618.4+1.2Aircraft, Defense & Space (ADS)837.0-345.0891.2+201.6105.3+35.6Others, Corporate & Eliminations (OC&E)-0.6-15.09.9-17.4-34.2+6.8Total5,029.1+561.03,326.9+279.9301.2+61.1(Note) Q1-3 FY2024 results on which YoY figures are based have been retroactively adjusted to reflect the planned sale of ML shares.In Energy, order intake increased by ¥889.9 billion YoY mainly due to continued strong demand in Gas Turbine Combined Cycle (GTCC). Contracts for 31 large frame gas turbine units—up 15 units YoY—were concluded during Q1-3, the majority of which were from customers in North America and Asia. Revenue increased by ¥75.9 billion YoY; the largest gains were seen in GTCC, which continued to execute its sizeable backlog. Segment business profit decreased by ¥7.7 billion YoY mainly due to one-time expenses in Steam Power, which offset strong performance in GTCC from higher revenue and improved margins.In P&I, order intake increased by ¥77.7 billion YoY due to the booking of a large project in Engineering. Revenue grew by ¥47.4 billion. Improved margins in Metals Machinery and Machinery Systems helped to raise segment business profit by ¥25.2 billion YoY.In LT&D, revenue decreased by ¥27.6 billion YoY due to a decline in units sold in Turbochargers and Heating, Ventilation & Air Conditioning (HVAC). Steady performance in Engines on the back of strong demand in Asia, combined with the rebound from one-time expenses associated with a supply chain disruption in Turbochargers during the previous fiscal year, resulted in a ¥1.2 billion YoY increase in segment business profit.In ADS, order intake decreased by ¥345.0 billion YoY due to a high base effect from large orders booked in Defense & Space during the previous fiscal year. Revenue increased by ¥201.6 billion YoY, mainly in Defense & Space, where steady progress in backlog execution continued. Increased revenue and higher margins in Defense & Space and Commercial Aviation served to increase segment business profit by ¥35.6 billion YoY.FY2025 Earnings ForecastMHI revised its guidance for the period ending March 31, 2026, increasing the forecasts for order intake, business profit, net income, EBITDA, and FCF over the previous announcement made November 7, 2025, based on stronger-than-anticipated performance through Q3. The full-year dividend forecast of 24 yen per share was unchanged.(billion yen, except where otherwise stated)FY2025 Earnings ForecastFY2024Actual (Note)FY2025Forecast(Previous)FY2025Forecast(Revised)Revised vs.PreviousOrder Intake6,405.16,100.06,700.0+600.0Revenue4,361.14,800.04,800.0-Profit from Business ActivitiesProfit Margin354.98.1%390.08.1%410.08.5%+20.0+0.4 ptsProfit Attributable to Owners of ParentProfit Margin245.45.6%230.04.8%260.05.4%+30.0+0.6 ptsROE10.7%10%10%-EBITDAEBITDA Margin469.910.8%510.010.6%530.011.0%+20.0+0.4 ptsFCF342.70.0200.0+200.0Dividends23 yen24 yen24 yen-(Note) FY2024 results have been retroactively adjusted to reflect the planned sale of ML shares.(billion yen, except where otherwise stated)FY2025 Earnings Forecast by SegmentOrder IntakeRevenueBusiness ProfitPreviousRevisedPreviousRevisedPreviousRevisedEnergy3,200.03,600.02,000.02,000.0240.0240.0P&I900.01,100.0850.0850.070.080.0LT&D600.0600.0600.0600.020.020.0ADS1,400.01,400.01,350.01,350.0140.0140.0OC&E0.00.00.00.0-80.0-70.0Total6,100.06,700.04,800.04,800.0390.0410.0 CFO Message"In the first three quarters of this fiscal year, we continued to build on the strong performance I shared with you in our last release, with all major financial indicators up year-on-year, especially order intake and business profit," MHI Chief Financial Officer Hiroshi Nishio commented. Nishio continued, "Looking at individual businesses, GTCC drove strong order intake performance, booking 31 large frame gas turbine units mainly in North America and Asia. Demand for gas turbines remains high, particularly in the U.S., as communicated previously. Revenue was up especially in GTCC and Defense & Space, which are both executing some of the largest backlogs ever seen in our history. We also achieved remarkable growth in business profit as we offset one-time expenses in Steam Power with success in other businesses.""On the back of this excellent progress through Q3," Nishio went on, "we have made upward revisions to our full-year order intake, business profit, net income, and FCF guidance. We are entering the final stretch of this fiscal year with renewed confidence, leveraging our historically high backlog to grow profit while continuing to win new orders—the source of future earnings expansion. As we aim to meet these updated targets, we ask our shareholders and other stakeholders to look forward to our next release later this year."Attachment 1: Q1-3 FY2025 Financial ResultsFinancial ResultsAttachment 2: Presentation Materials of Financial ResultsPresentation MaterialsDownloadable PDF of this press releasePress ReleaseNote regarding forward looking statements:Forecasts regarding future performance outlined in these materials are based on judgments made in accordance with information available at the time they were prepared. As such, these projections include risk and uncertainty. Investors are recommended not to depend solely on these projections when making investment decisions. Actual results may vary significantly from these projections due to a number of factors, including, but not limited to, economic trends affecting the Company's operating environment, fluctuations in the value of the Japanese yen to the U.S. dollar and other foreign currencies, and trends in Japan's stock markets. The results projected here should not be construed in any way as a guarantee by the Company.In response to U.S. tariff policy, the Company is pursuing mitigation strategies focused on cost passthroughs. As of the date of this release, the Company expects any impact on performance to be limited in nature.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com